School of Medicine, The Maldives National University, Male', Maldives.
Eur Rev Med Pharmacol Sci. 2020 Feb;24(4):2006-2011. doi: 10.26355/eurrev_202002_20378.
The World Health Organization (WHO) has issued a warning that, although the 2019 novel coronavirus (COVID-19) from Wuhan City (China), is not pandemic, it should be contained to prevent the global spread. The COVID-19 virus was known earlier as 2019-nCoV. As of 12 February 2020, WHO reported 45,171 cases and 1115 deaths related to COVID-19. COVID-19 is similar to Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) virus in its pathogenicity, clinical spectrum, and epidemiology. Comparison of the genome sequences of COVID-19, SARS-CoV, and Middle East Respiratory Syndrome coronavirus (MERS-CoV) showed that COVID-19 has a better sequence identity with SARS-CoV compared to MERS CoV. However, the amino acid sequence of COVID-19 differs from other coronaviruses specifically in the regions of 1ab polyprotein and surface glycoprotein or S-protein. Although several animals have been speculated to be a reservoir for COVID-19, no animal reservoir has been already confirmed. COVID-19 causes COVID-19 disease that has similar symptoms as SARS-CoV. Studies suggest that the human receptor for COVID-19 may be angiotensin-converting enzyme 2 (ACE2) receptor similar to that of SARS-CoV. The nucleocapsid (N) protein of COVID-19 has nearly 90% amino acid sequence identity with SARS-CoV. The N protein antibodies of SARS-CoV may cross react with COVID-19 but may not provide cross-immunity. In a similar fashion to SARS-CoV, the N protein of COVID-19 may play an important role in suppressing the RNA interference (RNAi) to overcome the host defense. This mini-review aims at investigating the most recent trend of COVID-19.
世界卫生组织(WHO)发出警告称,虽然来自中国武汉市的 2019 年新型冠状病毒(COVID-19)尚未构成大流行,但应加以控制,以防止其在全球范围内传播。COVID-19 病毒之前被称为 2019-nCoV。截至 2020 年 2 月 12 日,世卫组织报告了与 COVID-19 相关的 45171 例病例和 1115 例死亡。COVID-19 在其致病性,临床谱和流行病学方面与严重急性呼吸系统综合症冠状病毒(SARS-CoV)病毒相似。COVID-19、SARS-CoV 和中东呼吸综合征冠状病毒(MERS-CoV)的基因组序列比较表明,COVID-19 与 SARS-CoV 的序列同一性优于 MERS CoV。但是,COVID-19 的氨基酸序列与其他冠状病毒在 1ab 多蛋白和表面糖蛋白或 S 蛋白区域特异性不同。尽管已经推测了几种动物可能是 COVID-19 的宿主,但尚未确认任何动物宿主。COVID-19 引起的 COVID-19 疾病与 SARS-CoV 具有相似的症状。研究表明,COVID-19 的人类受体可能是血管紧张素转换酶 2(ACE2)受体,类似于 SARS-CoV。COVID-19 的核衣壳(N)蛋白与 SARS-CoV 有近 90%的氨基酸序列同一性。SARS-CoV 的 N 蛋白抗体可能与 COVID-19 发生交叉反应,但可能无法提供交叉免疫力。与 SARS-CoV 相似,COVID-19 的 N 蛋白可能在抑制 RNA 干扰(RNAi)以克服宿主防御方面发挥重要作用。本综述旨在探讨 COVID-19 的最新趋势。
Eur Rev Med Pharmacol Sci. 2020-2
Malays J Pathol. 2020-4
Eur Rev Med Pharmacol Sci. 2020-2
Int Braz J Urol. 2020-7
Przegl Epidemiol. 2020
Eur Rev Med Pharmacol Sci. 2020-5
Crit Rev Clin Lab Sci. 2020-7-9
New Microbes New Infect. 2024-10-24
Environ Chall (Amst). 2021-4
Behav Sci (Basel). 2023-11-21